Form 4: Karyopharm Therapeutics CEO Richard Paulson Awarded Restricted Stock Units
SEC Form 4 Filing
Karyopharm Therapeutics CEO Richard Paulson received 442,800 restricted stock units (RSUs) on February 28, 2024, which will vest in three equal annual installments starting February 28, 2025.
Summary
- Richard A. Paulson, CEO of Karyopharm Therapeutics Inc., was granted 442,800 restricted stock units (RSUs) on February 28, 2024.
- These RSUs were awarded under the company's 2022 Equity Incentive Plan, as amended.
- The RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.
- The RSUs will vest in three equal annual installments, commencing on February 28, 2025.
- Following the reported transaction, Paulson beneficially owns 1,264,253 shares of common stock.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of RSUs is a standard practice and indicates confidence in the CEO's leadership. The vesting schedule promotes long-term alignment.
Positives
- The grant of RSUs to the CEO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
- The vesting schedule encourages long-term commitment from the CEO.
Future Outlook
The vesting of the RSUs is contingent upon the CEO's continued service with the company.
Industry Context
Equity compensation is a common practice in the pharmaceutical industry to attract and retain top executive talent and align their interests with those of shareholders.
Comparison to Industry Standards
- Equity grants to CEOs in the biopharmaceutical industry vary widely depending on company size, performance, and stage of development.
- Comparing the size and vesting schedule of this RSU grant to those of CEOs at similar-sized companies like Exelixis or Blueprint Medicines could provide further context.
- Industry benchmarks for equity compensation often consider factors such as total shareholder return and achievement of specific milestones.
Stakeholder Impact
- Shareholders may view the RSU grant positively as it aligns the CEO's interests with theirs.
- Employees may see the grant as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 02/28/2024 | Date of transaction: Richard Paulson was awarded 442,800 restricted stock units. |
| 02/28/2025 | First vesting date: The RSUs vest in three equal annual installments beginning on this date. |
| 02/29/2024 | Date of signature: The Form 4 was signed on this date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.